Cel-Sci announced plans to raise $5 million in funding through a stock offering in an effort to expedite the development of a technology to treat swine flu. The company said it also will use the money on a $15 million production facility in Baltimore that would focus on manufacturing Multikine, a drug for late-stage head and neck cancers.

Related Summaries